CF Foundation Invests $3M to Support Phage Therapy, AP-PA02

The Cystic Fibrosis (CF) Foundation has invested $3 million in Armata Pharmaceuticals to support development of AP-PA02, a bacteriophage now being evaluated in a clinical trial for its ability to treat respiratory infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF). “We are pleased by…

Q&A With JP Clancy, VP of Clinical Research at the CF Foundation

When it comes to raising funds for cystic fibrosis (CF), the Cystic Fibrosis Foundation is committed to relentlessly pursuing research initiatives until “CF stands for cure found.” Last year, the foundation put a total of $218.1 million toward research and spent $80 million on its…

FDA Clears Clinical Trial of AP-PA02 Phage Therapy for P. aeruginosa Infections

The U.S. Food and Drug Administration (FDA) cleared Armata Pharmaceuticals‘ investigational new drug (IND) application for a Phase 1b/2a clinical trial of AP-PA02 for the treatment of the Pseudomonas aeruginosa bacterial infections that are a hallmark of cystic fibrosis (CF). “We are very pleased…

Armata Receives Up to $5M From CF Foundation to Develop Phage Therapy AP-PA02

The Cystic Fibrosis Foundation has awarded up to $5 million to Armata Pharmaceuticals to advance its potential treatment AP-PA02 — a phage therapy against multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients — into a Phase 1b/2 clinical trial. Phage therapy harnesses the properties of …

Armata Announces New Treatment Candidate for P. Aeruginosa Infections in CF Patients

Armata Pharmaceuticals is going to target multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients with its new enhanced bacteriophage candidate AP-PA02, the company announced. AP-PA02 is being developed to replace…